The Past decade has seen significant advances in cancer immunotherapy with the development of multiple strategies including monoclonal antibodies targeting checkpoint blockers, oncolytic viruses, fusion proteins and cell therapies such as tumor-specific chimeric antigen receptor (CAR-) T cell therapy, NK cell therapy and ?d-T-cell therapy. Multiple cell therapies including sipuleucel-T (Provange), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have been approved by the US FDA for different hematological cancers and hormone-refractory prostate cancer (Provange). Impressive results were noted with CAR-T cell therapy with objective response rates (ORR) as high as 100% in certain hematological cancers and with responses durable over 10 years in some patients.
New studies aiming at improving the durability of responses, reducing the toxicity, extending the success to solid tumors, and at addressing the concerns related to time to manufacture of cell therapy are currently underway. Early clinical and preclinical studies on novel binding domains such as D-domains, universal CAR-T cells, off-the-shelf allogeneic CAR-T cells, and NK cells have shown promising results. Similarly, the use of bispecific CAR-T cells and a cocktail of CAR-T cells also showed potential. Given the potential of cell therapy, the goal of the special issue is to provide a platform to publish and discuss novel cutting-edge research in the field.
This special issue aims to broadly attract research on cell therapy for the treatment of cancer. Both clinical and preclinical research-based original articles, systematic reviews with or without meta-analysis as well as narrative reviews are within the scope of the special issue. Case reports may be considered if they include detailed elucidation of molecular mechanisms.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The Past decade has seen significant advances in cancer immunotherapy with the development of multiple strategies including monoclonal antibodies targeting checkpoint blockers, oncolytic viruses, fusion proteins and cell therapies such as tumor-specific chimeric antigen receptor (CAR-) T cell therapy, NK cell therapy and ?d-T-cell therapy. Multiple cell therapies including sipuleucel-T (Provange), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have been approved by the US FDA for different hematological cancers and hormone-refractory prostate cancer (Provange). Impressive results were noted with CAR-T cell therapy with objective response rates (ORR) as high as 100% in certain hematological cancers and with responses durable over 10 years in some patients.
New studies aiming at improving the durability of responses, reducing the toxicity, extending the success to solid tumors, and at addressing the concerns related to time to manufacture of cell therapy are currently underway. Early clinical and preclinical studies on novel binding domains such as D-domains, universal CAR-T cells, off-the-shelf allogeneic CAR-T cells, and NK cells have shown promising results. Similarly, the use of bispecific CAR-T cells and a cocktail of CAR-T cells also showed potential. Given the potential of cell therapy, the goal of the special issue is to provide a platform to publish and discuss novel cutting-edge research in the field.
This special issue aims to broadly attract research on cell therapy for the treatment of cancer. Both clinical and preclinical research-based original articles, systematic reviews with or without meta-analysis as well as narrative reviews are within the scope of the special issue. Case reports may be considered if they include detailed elucidation of molecular mechanisms.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
